Table 1.
Baseline characteristics of study participants*
| Placebo | Resveratrol | P-value | |
|---|---|---|---|
| Age, years | 53 ± 2# | 53 ± 2# | N/A |
| Body weight, kg | 100.1 ± 3.5 | 99.6 ± 3.7 | 0.50 |
| BMI, kg/m[2] | 31.6 ± 0.7 | 31.4 ± 0.8 | 0.48 |
| Body fat, % | 26.4 ± 0.53# | 26.4 ± 0.53# | N/A |
| Systolic blood pressure, mmHg | 131 ± 3.1 | 132 ± 3.0 | 0.22 |
| Diastolic blood pressure, mmHg | 82 ± 2.5 | 83 ± 2.6 | 0.20 |
| Glucose, mmol/l | 5.44 ± 0.10 | 5.44 ± 0.13 | 0.96 |
| Insulin, mU/l | 16.37 ± 1.76 | 15.38 ± 2.05 | 0.67 |
| Triglycerides, mmol/l | 1.86 ± 0.19 | 1.92 ± 0.21 | 0.80 |
| Nonesterified fatty acids, μmol/l | 357 ± 69 | 320 ± 31 | 0.56 |
Characteristics of participants measured at the start of each intervention period (day 0). Values are given as mean ± SEM. *Data obtained from Timmers et. al 201111; #Only measured once, at the start of the first intervention period by dual-energy X-ray absorptiometry; N/A, not applicable